Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Caroline M Emery"'
Autor:
Anupama Reddy, Joseph D Growney, Nick S Wilson, Caroline M Emery, Jennifer A Johnson, Rebecca Ward, Kelli A Monaco, Joshua Korn, John E Monahan, Mark D Stump, Felipa A Mapa, Christopher J Wilson, Janine Steiger, Jebediah Ledell, Richard J Rickles, Vic E Myer, Seth A Ettenberg, Robert Schlegel, William R Sellers, Heather A Huet, Joseph Lehár
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0146635 (2016)
Externí odkaz:
https://doaj.org/article/59c3f93f2d5c4482aef340a64a791f66
Autor:
Anupama Reddy, Joseph D Growney, Nick S Wilson, Caroline M Emery, Jennifer A Johnson, Rebecca Ward, Kelli A Monaco, Joshua Korn, John E Monahan, Mark D Stump, Felipa A Mapa, Christopher J Wilson, Janine Steiger, Jebediah Ledell, Richard J Rickles, Vic E Myer, Seth A Ettenberg, Robert Schlegel, William R Sellers, Heather A Huet, Joseph Lehár
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0138486 (2015)
Death Receptor 5 (DR5) agonists demonstrate anti-tumor activity in preclinical models but have yet to demonstrate robust clinical responses. A key limitation may be the lack of patient selection strategies to identify those most likely to respond to
Externí odkaz:
https://doaj.org/article/65b59ba5d911495fa33f7b9acb527174
Autor:
Laura E MacConaill, Catarina D Campbell, Sarah M Kehoe, Adam J Bass, Charles Hatton, Lili Niu, Matt Davis, Keluo Yao, Megan Hanna, Chandrani Mondal, Lauren Luongo, Caroline M Emery, Alissa C Baker, Juliet Philips, Deborah J Goff, Michelangelo Fiorentino, Mark A Rubin, Kornelia Polyak, Jennifer Chan, Yuexiang Wang, Jonathan A Fletcher, Sandro Santagata, Gianni Corso, Franco Roviello, Ramesh Shivdasani, Mark W Kieran, Keith L Ligon, Charles D Stiles, William C Hahn, Matthew L Meyerson, Levi A Garraway
Publikováno v:
PLoS ONE, Vol 4, Iss 11, p e7887 (2009)
Detection of critical cancer gene mutations in clinical tumor specimens may predict patient outcomes and inform treatment options; however, high-throughput mutation profiling remains underdeveloped as a diagnostic approach. We report the implementati
Externí odkaz:
https://doaj.org/article/388609211758433580e680225740cbc3
Autor:
Dean J. Welsch, Saurabh Saha, Caroline M. Emery, Mark Namchuk, Gary DeCrescenzo, Anna Groover, Kathryn Meshaw, Ramin Samadani, Michael J. Wick, Paul Shapiro, Matthew Fitzgibbon, Gabriel Martinez-Botella, David A. Sorrell, Diane M. Boucher, Michael Hale, Jeffrey J. Roix, Alex M. Aronov, Russell R. Hoover, William Markland, Brinley F. Furey, Ursula A. Germann
Supplementary materials and methods and supplementary figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2691c8ce88b24315d90208e7f0fa7411
https://doi.org/10.1158/1535-7163.22508691.v1
https://doi.org/10.1158/1535-7163.22508691.v1
Autor:
Bob T. Li, David M. Hyman, Dean J. Welsch, Mary Varterasian, Saurabh Saha, Anna L. Groover, Caroline M. Emery, Gary A. DeCrescenzo, Sapna P. Patel, Antoni Ribas, Mario E. Lacouture, Anna M. Varghese, Richard D. Carvajal, Elizabeth Buchbinder, Keith Flaherty, Mario Sznol, Andrea Wang-Gillam, Anthony W. Tolcher, James W. Mier, Geoffrey I. Shapiro, Manish R. Patel, Vicki Keedy, Jeffrey A. Sosman, Deborah Jean Lee Wong, Filip Janku, Jeffrey R. Infante, Ryan J. Sullivan
Tumor types and molecular alterations of enrolled patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7056746bff2432eadfcb1840e1a0b9f9
https://doi.org/10.1158/2159-8290.22532095.v1
https://doi.org/10.1158/2159-8290.22532095.v1
Autor:
Dean J. Welsch, Saurabh Saha, Caroline M. Emery, Mark Namchuk, Gary DeCrescenzo, Anna Groover, Kathryn Meshaw, Ramin Samadani, Michael J. Wick, Paul Shapiro, Matthew Fitzgibbon, Gabriel Martinez-Botella, David A. Sorrell, Diane M. Boucher, Michael Hale, Jeffrey J. Roix, Alex M. Aronov, Russell R. Hoover, William Markland, Brinley F. Furey, Ursula A. Germann
In SW48 colorectal cells engineered with KRAS alleles, response to paclitaxel was unaltered.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37056904b019df912ca990e86321623e
https://doi.org/10.1158/1535-7163.22508697.v1
https://doi.org/10.1158/1535-7163.22508697.v1
Supplementary Figure Legends - PDF file 92K, Supplementary figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdf849cacb0134a210ed0112d4f20fef
https://doi.org/10.1158/0008-5472.22397753.v1
https://doi.org/10.1158/0008-5472.22397753.v1
Supplementary Material - PDF file 1876K, Supplementary Figure S1. Characterization of mutants obtained from B-RAFV600E random mutagenesis screens Supplementary Figure S2. Biochemical characterization of C-RAF resistance alleles Supplementary Figure S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a14d865d0ed8e511ce0839b53cf3143
https://doi.org/10.1158/0008-5472.22397750.v1
https://doi.org/10.1158/0008-5472.22397750.v1
Autor:
Deborah Knoerzer, Anupama Reddy, Jessica A. Box, Anna Groover, Brent Kreider, Martin Teresk, Caroline M. Emery
Publikováno v:
Cancer Research. 83:2692-2692
Ulixertinib (BVD-523) is a first-in-class and best-in-class small molecule inhibitor of ERK1/2 currently being investigated in several oncology clinical trials, both as a single agent and in combination with other therapeutics. Ulixertinib has demons
Autor:
Caroline M. Emery, Brian Corgiat, Justin Davis, David Sorrell, Mitch Johnson, Brent Kreider, Deborah Knoerzer
Publikováno v:
Cancer Research. 82:1057-1057
Ulixertinib (BVD-523) is a first-in-class small molecule inhibitor of ERK1/2 currently being investigated in several oncology clinical trials, both as a single agent and in combination with other anti-cancer therapeutics. Palbociclib and ribociclib a